Plain-English translation of NCT06413992 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 2 โ Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new treatment approach for people with advanced or recurrent endometrial cancer that has a TP53 gene mutation. The trial combines three types of cancer-fighting medicines: chemotherapy drugs (paclitaxel and ), an immunotherapy drug called , and a targeted medicine called . The goal is to see if this combination can help control the cancer better than standard treatments.
Current treatments don't work equally well for all patients with this type of cancer, especially those in Asia and those with the TP53 gene mutation. Recent studies suggest that combining chemotherapy with immunotherapy, and adding a targeted medicine that works with the immune system, might help more people. This trial is designed to find the best way to combine these medicines for patients with this specific genetic mutation.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You would receive chemotherapy and immunotherapy infusions intravenously every 3 weeks for 6 cycles (about 4.5 months). Then you would move into a maintenance phase where you continue the immunotherapy infusions every 3 weeks and take oral targeted medication twice daily, continuing for up to 2 years or until the cancer progresses or side effects become too difficult. You would have regular clinic visits for blood tests, scans, and check-ins with your medical team throughout the trial.
AI-generated summary from trial data ยท Jun 10, 2026 ยท Not medical advice
China